CAR T cell therapy for B-cell lymphomas
B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a signific...
Gespeichert in:
| Veröffentlicht in: | Best practice & research. Clinical haematology 2018-06, Vol.31 (2), p.135-146 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 2 |
| container_start_page | 135 |
| container_title | Best practice & research. Clinical haematology |
| container_volume | 31 |
| creator | Chavez, Julio C. Locke, Frederick L. |
| description | B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs. |
| doi_str_mv | 10.1016/j.beha.2018.04.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6716161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521692618300227</els_id><sourcerecordid>2056759802</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-86cd37241f3e70c6d258903f92781f425ed61346f0390ca28522c427cc15ebf73</originalsourceid><addsrcrecordid>eNp9kMtK7EAQhhs54v0FXEh2x01idfUlaZADOngDQRBdNz2dipMhmYzdGWHe3sRR8WykFlV0_fV31cfYMYeMA9dn82xKM5ch8CIDmQHwLbbHlcCUG5R_xhp5qg3qXbYf4xxACINih-2iMWAMl3vs7-TiMXlKPDVN0s8ouOU6qbqQXKYfT826Xc661sVDtl25JtLRZz5gz9dXT5Pb9P7h5m5ycZ96qVSfFtqXIkfJK0E5eF2iKgyIymBe8EqiolJzIXUFwoB3WChELzH3niuaVrk4YP82vsvVtKXS06IPrrHLULcurG3navt_Z1HP7Ev3ZnXO9RCDwemnQeheVxR729ZxvMUtqFtFi6B0rkwBOEhxI_WhizFQ9f0NBzsStnM7ErYjYQvSDoSHoZOfC36PfCEdBOcbAQ2Y3moKNvqaFp7KOpDvbdnVv_m_A9M_il8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2056759802</pqid></control><display><type>article</type><title>CAR T cell therapy for B-cell lymphomas</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Chavez, Julio C. ; Locke, Frederick L.</creator><creatorcontrib>Chavez, Julio C. ; Locke, Frederick L.</creatorcontrib><description>B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.</description><identifier>ISSN: 1521-6926</identifier><identifier>EISSN: 1532-1924</identifier><identifier>DOI: 10.1016/j.beha.2018.04.001</identifier><identifier>PMID: 29909914</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Aggressive lymphomas ; Antigens, CD19 - immunology ; CART ; Diffuse large B cell lymphoma ; Humans ; Immunotherapy ; Immunotherapy, Adoptive - methods ; Lymphoma, Follicular - immunology ; Lymphoma, Follicular - pathology ; Lymphoma, Follicular - therapy ; Lymphoma, Large B-Cell, Diffuse - immunology ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Multicenter Studies as Topic ; Receptors, Chimeric Antigen - immunology ; Receptors, Chimeric Antigen - therapeutic use ; Refractory ; Risk Factors</subject><ispartof>Best practice & research. Clinical haematology, 2018-06, Vol.31 (2), p.135-146</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-86cd37241f3e70c6d258903f92781f425ed61346f0390ca28522c427cc15ebf73</citedby><cites>FETCH-LOGICAL-c455t-86cd37241f3e70c6d258903f92781f425ed61346f0390ca28522c427cc15ebf73</cites><orcidid>0000-0001-9063-6691</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.beha.2018.04.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29909914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chavez, Julio C.</creatorcontrib><creatorcontrib>Locke, Frederick L.</creatorcontrib><title>CAR T cell therapy for B-cell lymphomas</title><title>Best practice & research. Clinical haematology</title><addtitle>Best Pract Res Clin Haematol</addtitle><description>B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.</description><subject>Aggressive lymphomas</subject><subject>Antigens, CD19 - immunology</subject><subject>CART</subject><subject>Diffuse large B cell lymphoma</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy, Adoptive - methods</subject><subject>Lymphoma, Follicular - immunology</subject><subject>Lymphoma, Follicular - pathology</subject><subject>Lymphoma, Follicular - therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - immunology</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Multicenter Studies as Topic</subject><subject>Receptors, Chimeric Antigen - immunology</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>Refractory</subject><subject>Risk Factors</subject><issn>1521-6926</issn><issn>1532-1924</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtK7EAQhhs54v0FXEh2x01idfUlaZADOngDQRBdNz2dipMhmYzdGWHe3sRR8WykFlV0_fV31cfYMYeMA9dn82xKM5ch8CIDmQHwLbbHlcCUG5R_xhp5qg3qXbYf4xxACINih-2iMWAMl3vs7-TiMXlKPDVN0s8ouOU6qbqQXKYfT826Xc661sVDtl25JtLRZz5gz9dXT5Pb9P7h5m5ycZ96qVSfFtqXIkfJK0E5eF2iKgyIymBe8EqiolJzIXUFwoB3WChELzH3niuaVrk4YP82vsvVtKXS06IPrrHLULcurG3navt_Z1HP7Ev3ZnXO9RCDwemnQeheVxR729ZxvMUtqFtFi6B0rkwBOEhxI_WhizFQ9f0NBzsStnM7ErYjYQvSDoSHoZOfC36PfCEdBOcbAQ2Y3moKNvqaFp7KOpDvbdnVv_m_A9M_il8</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Chavez, Julio C.</creator><creator>Locke, Frederick L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9063-6691</orcidid></search><sort><creationdate>20180601</creationdate><title>CAR T cell therapy for B-cell lymphomas</title><author>Chavez, Julio C. ; Locke, Frederick L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-86cd37241f3e70c6d258903f92781f425ed61346f0390ca28522c427cc15ebf73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aggressive lymphomas</topic><topic>Antigens, CD19 - immunology</topic><topic>CART</topic><topic>Diffuse large B cell lymphoma</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy, Adoptive - methods</topic><topic>Lymphoma, Follicular - immunology</topic><topic>Lymphoma, Follicular - pathology</topic><topic>Lymphoma, Follicular - therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - immunology</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Multicenter Studies as Topic</topic><topic>Receptors, Chimeric Antigen - immunology</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>Refractory</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chavez, Julio C.</creatorcontrib><creatorcontrib>Locke, Frederick L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Best practice & research. Clinical haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chavez, Julio C.</au><au>Locke, Frederick L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CAR T cell therapy for B-cell lymphomas</atitle><jtitle>Best practice & research. Clinical haematology</jtitle><addtitle>Best Pract Res Clin Haematol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>31</volume><issue>2</issue><spage>135</spage><epage>146</epage><pages>135-146</pages><issn>1521-6926</issn><eissn>1532-1924</eissn><abstract>B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29909914</pmid><doi>10.1016/j.beha.2018.04.001</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-9063-6691</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6926 |
| ispartof | Best practice & research. Clinical haematology, 2018-06, Vol.31 (2), p.135-146 |
| issn | 1521-6926 1532-1924 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6716161 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Aggressive lymphomas Antigens, CD19 - immunology CART Diffuse large B cell lymphoma Humans Immunotherapy Immunotherapy, Adoptive - methods Lymphoma, Follicular - immunology Lymphoma, Follicular - pathology Lymphoma, Follicular - therapy Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Multicenter Studies as Topic Receptors, Chimeric Antigen - immunology Receptors, Chimeric Antigen - therapeutic use Refractory Risk Factors |
| title | CAR T cell therapy for B-cell lymphomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A51%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CAR%20T%20cell%20therapy%20for%20B-cell%20lymphomas&rft.jtitle=Best%20practice%20&%20research.%20Clinical%20haematology&rft.au=Chavez,%20Julio%20C.&rft.date=2018-06-01&rft.volume=31&rft.issue=2&rft.spage=135&rft.epage=146&rft.pages=135-146&rft.issn=1521-6926&rft.eissn=1532-1924&rft_id=info:doi/10.1016/j.beha.2018.04.001&rft_dat=%3Cproquest_pubme%3E2056759802%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2056759802&rft_id=info:pmid/29909914&rft_els_id=S1521692618300227&rfr_iscdi=true |